Cargando…

Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study

BACKGROUND: The incidence of Clostridioides difficile infection (CDI) is increasing in the general population. Data on the epidemiology of CDI in peripartum women – a highly vulnerable patient population – is scarce. The objective of this study was to report the incidence of CDI in peripartum women....

Descripción completa

Detalles Bibliográficos
Autores principales:	Saha, Srishti, Pardi, Ryan, Theiler, Regan N., Pardi, Darrell S., Khanna, Sahil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385813/ https://www.ncbi.nlm.nih.gov/pubmed/32782480 http://dx.doi.org/10.1177/1756284820942621

Ejemplares similares

Effect of peripartum Clostridioides difficile infection on pregnancy and neonatal outcomes: an observational study
por: Saha, Srishti, et al.
Publicado: (2023)

Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection
por: Saha, Srishti, et al.
Publicado: (2021)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

Clostridioides difficile infection: curbing a difficult menace
por: Khanna, Sahil, et al.
Publicado: (2022)

Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2023)

Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection
por: Voth, Elida, et al.
Publicado: (2021)

Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection
por: Sehgal, Kanika, et al.
Publicado: (2021)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2021)

Management of Clostridioides difficile colitis: insights for the gastroenterologist
por: Saha, Srishti, et al.
Publicado: (2019)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

Outcomes in children with Clostridium difficile infection: results from a nationwide survey
por: Gupta, Arjun, et al.
Publicado: (2016)

1620 Extraintestinal Clostridium difficile infections: A Single Center Experience
por: Gupta, Arjun, et al.
Publicado: (2014)

In reply—Lack of Marked Association Between Gastrointestinal Symptoms and COVID-19 Mortality: An Updated Meta-analysis Based on Adjusted Effect Estimates
por: Tariq, Raseen, et al.
Publicado: (2021)

Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2018)

A268 RESOLUTION RATES IN OPEN-LABEL VERSUS RANDOMIZED CONTROLLED TRIALS FOR MICROBIOTA RESTORATION FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: AN UPDATED META-ANALYSIS
por: Tariq, R, et al.
Publicado: (2023)

Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2020)

Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice
por: Tariq, Raseen, et al.
Publicado: (2017)

Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations
por: Khanna, Sahil, et al.
Publicado: (2021)

Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2017)

Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings
por: Cho, Janice M., et al.
Publicado: (2019)

Management of Clostridioides difficile infection in patients with inflammatory bowel disease
por: Khanna, Sahil
Publicado: (2021)

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials
por: Sims, Matthew, et al.
Publicado: (2021)

The interplay of Clostridioides difficile infection and inflammatory bowel disease
por: Sehgal, Kanika, et al.
Publicado: (2021)

The interplay of SARS-CoV-2 and Clostridioides difficile infection
por: Khanna, Sahil, et al.
Publicado: (2021)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface
por: Sehgal, Kanika, et al.
Publicado: (2021)

Immune response against Clostridioides difficile and translation to therapy
por: Sehgal, Kanika, et al.
Publicado: (2021)

The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
por: Seekatz, Anna Maria, et al.
Publicado: (2022)

Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2
por: Yadav, Devvrat, et al.
Publicado: (2021)

Clostridioides difficile Infection and Liver Cirrhosis – A Retrospective, Cohort Study
por: Mantri, Nikhitha, et al.
Publicado: (2021)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
por: McGovern, Barbara H, et al.
Publicado: (2020)

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort
por: Venkat, Preethi G., et al.
Publicado: (2022)

The natural history of histological changes in microscopic colitis
por: Sehgal, Kanika, et al.
Publicado: (2023)

Extraintestinal Clostridioides difficile infection
por: Hai, Zhao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9u8fvafbjssj0bh0cvmdsh3q4v